Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Disorders01:29

Bone Disorders

8.8K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
8.8K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

266
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
266
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

367
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
367
Bone Remodeling01:40

Bone Remodeling

41.3K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
41.3K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

4.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.9K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

364
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
364

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unsolved Issues in Managing CKD-Associated Osteoporosis: Myths, Facts, and Clinical Grey Zones.

Kidney360·2026
Same author

Prevalence, predictors, and clinical impact of vitamin D deficiency on 12-month outcomes in hip fracture patients.

Journal of endocrinological investigation·2026
Same author

Second interim analysis of the post-authorisation safety study (PASS) of burosumab in paediatric patients with X-linked hypophosphataemia.

European journal of endocrinology·2026
Same author

Under-recognized, under-referred: a multidisciplinary evaluation of fragility fracture management in the emergency setting.

Archives of osteoporosis·2026
Same author

The time has come for comprehensive geriatric assessment in internal medicine.

European journal of internal medicine·2026
Same author

REMS versus DXA in older adults: diagnostic concordance for osteoporosis in a geriatric outpatient population.

Archives of osteoporosis·2026

Related Experiment Video

Updated: Apr 18, 2026

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
05:55

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head

Published on: September 27, 2024

1.1K

Hepatic osteodystrophy.

Angelo Gatta1, Alberto Verardo1, Marco Di Pascoli1

  • 1Department of Medicine - DIMED, University of Padua, Padua, Italy.

Clinical Cases in Mineral and Bone Metabolism : the Official Journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases
|January 9, 2015
PubMed
Summary

Patients with chronic liver disease frequently experience metabolic bone disturbances, including osteoporosis. Screening and management are crucial, especially post-liver transplant, to mitigate bone density loss and improve prognosis.

Keywords:
hepatic osteodystrophyliver cirrhosisliver transplantationvitamin D

More Related Videos

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

1.6K
Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.5K

Related Experiment Videos

Last Updated: Apr 18, 2026

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
05:55

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head

Published on: September 27, 2024

1.1K
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

1.6K
Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.5K

Area of Science:

  • Hepatology
  • Endocrinology
  • Orthopedics

Background:

  • Metabolic bone disease is common in chronic liver disease (CLD), with osteoporosis affecting 12-55% of patients.
  • Osteoporosis prevalence is higher in primary biliary cirrhosis and increases significantly after liver transplantation.
  • Bone mineral density loss is rapid in the first six months post-transplant, impacting prognosis.

Purpose of the Study:

  • To review the clinical relevance of hepatic osteodystrophy in CLD and post-liver transplant.
  • To highlight screening recommendations and therapeutic strategies for bone metabolic disturbances in liver disease patients.

Main Methods:

  • Literature review of studies on bone metabolism in chronic liver disease and liver transplantation.
  • Analysis of diagnostic criteria and therapeutic interventions for hepatic osteodystrophy.

Main Results:

  • Densitometry screening is recommended for advanced CLD patients, particularly those with cholestatic etiology or other risk factors.
  • Bone density at transplantation is a critical prognostic indicator.
  • Lifestyle modifications, nutritional support, and judicious drug use are primary therapies.

Conclusions:

  • Hepatic osteodystrophy requires vigilant management, with early screening and risk factor control being paramount.
  • Bisphosphonates may be considered for osteoporosis treatment post-transplant, with careful consideration of potential gastrointestinal side effects.